TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Metrics to compare | TCRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTCRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.8x | −2.2x | −0.6x | |
PEG Ratio | 0.04 | −0.09 | 0.00 | |
Price/Book | 0.6x | 1.1x | 2.6x | |
Price / LTM Sales | 15.2x | 4.6x | 3.3x | |
Upside (Analyst Target) | 376.2% | 360.8% | 38.7% | |
Fair Value Upside | Unlock | 25.8% | 5.1% | Unlock |